Company / PP&E (Net)
Century Therapeutics, Inc. PP&E (Net) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$50.0M
FY2025
5-year range
$50.0M / $82.8M
FY2022-FY2025
Trend
-19.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $83M in FY2022 to $50M in FY2025.
Based on SEC 10-K filings.
$50M in FY2025 with a 3-year CAGR of -15.5%.
Declined from $72M to $50M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -15.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Century Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 3-year CAGR of -15.5%, indicating a declining trend.
- In FY2025, pp&e (net) decreased 19.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.0M | -19.5% |
| FY2024 | $62.1M | -13.3% |
| FY2023 | $71.7M | -13.4% |
| FY2022 | $82.8M | - |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026